# Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

> **NCT05753501** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 135 (actual)

## Conditions studied

- Hematologic Cancer

## Interventions

- **DRUG:** ABBV-101

## Key facts

- **NCT ID:** NCT05753501
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-09
- **Primary completion:** 2031-03
- **Final completion:** 2031-03
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05753501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05753501, "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05753501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*